430 results about "Serum glucose" patented technology

Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases.

Novel FBPase inhibitors of the formula I are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analogue is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analogue in conquering blood sugar.

The invention discloses an exendin-4 analogue.Under stimulation of the analogue, islet cell tumor cells INS-1 of a rat can secrete insulin significantly more actively than that under the simulation of wild exendin-4, and hypoglycemic activity in the body of a diabetic model mouse C57B L / KsJ-db / db is significantly better than that under the simulation of wild exendin-4; the exendin-4 analogue is useful to prevent, treat or alleviate diabetics and obesity as well as other diseases benefiting from glucose reduction, gastrointestinal activity inhibition and gastric emptying.

The invention discloses a traditional Chinese medicinal composition for treating the qi and blood deficiency blood stasis type diabetic feet. The symptoms of the qi and blood deficiency blood stasis type diabetic feet are common in the restoration stage of the diabetic foot disease, and comprise lasting wound disunion, dilute fester, amyotrophy and weakness light tongue nature, thin and white tongue fur, chest distress, purple face, body fatness, feebleness, encrusted affect foot skin, ecchymosis, stiffness, numbness and the like. The composition comprises oral medicines and external medicines, wherein the oral medicines comprise Rhizoma Corydalis, Radix Rehmanniae Preparata, Chinese angelica, Radix Astragali, Achyranthes bidentata, Salvia miltiorrhiza, prepared Polygonum multiflorum Thunb, Rhizoma Atractylodis Macrocephalae, Poria cocos, Radix Curcumae Aromaticae, safflower, Ligusticum wallichii, Millettia dielsiana, lumbricus, dendrobium, ground beetle, Chinese cassia, Semen Brassicae and Radix Paeoniae Rubra; and the external medicines comprise Manchurian wildginger, Radix Clematidis, Panax Notoginseng, Boswellia carteri, myrrh, rheum officinale, Amur Corktree Bark, dried alum, Glabrous Greenbrier Rhizome, fried Radix Sanguisorbae, safflower, Fructus Cnidii, Bletilla striata and Rhizoma Drynariae. The composition has the efficacies of qi and blood tonifying, channel freeing and blood circulation stimulating, channel warming and cold dispelling, stasis removing and pain relieving, qi and blood benefiting, and internal heat and dysphoria removing when the composition is orally taken, and has the efficacies of blood circulation activating, stasis removing, inflammation removing and flesh engendering when the composition is externally used. On one hand, the local micro-vascular impairment of the lower limbs is improved and the blood circulation is promoted to make necrotic tissues shed as fast as possible in order to reach tissue restoration; on the other hand, the oral medicines can effectively control the blood sugar, adjust the blood viscosity and reduce the blood pressure; and simultaneously the food infection is prevented to enhance the body immunity.

The present invention relates to methods of using a composition of lactoferrin for the treatment of diabetes mellitus as manifested by a reduction in the levels of serum glucose, blood pressure, obesity, or glycosylated hemoglobin (HbAlc).